Evidence map›Paper›PMID 34014582›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2021

Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project).

G B Langbroek, A Wolkerstorfer, S E R Horbach, P I Spuls, K M Kelly, S J Robertson, M I van Raath, F Al-Niaimi, T Kono, P Boixeda and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 12 countries.

G B LangbroekDepartment of Surgery, Amsterdam University Medical Center (UMC) Location AMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-9801-1415
A WolkerstorferDepartment of Dermatology, Amsterdam University Medical Center UMC, Amsterdam Public Health, Immunity and Infections, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-1421-1493
S E R HorbachDepartment of Plastic-, Reconstructive- and Hand Surgery, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands.
P I SpulsDepartment of Dermatology, Amsterdam University Medical Center UMC, Amsterdam Public Health, Immunity and Infections, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-6035-2863
K M KellyDepartment of Dermatology, University of California Irvine, Irvine, CA, USA.ORCID https://orcid.org/0000-0002-5988-2197
S J RobertsonDepartment of Dermatology and Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia.ORCID https://orcid.org/0000-0003-4790-9943
M I van RaathDepartment of Plastic, Reconstructive, and Hand Surgery, Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-5080-7019
F Al-NiaimiPrivate Dermatological Practice, London, UK.ORCID https://orcid.org/0000-0002-0684-4322
T KonoDepartment of Plastic Surgery, Tokai University School of Medicine, Shimokasuya Isehara Kanagawa, Kanagawa, Japan.
P BoixedaDepartment of Dermatology, Hospital Ramon y Cajal, Madrid, Spain.ORCID https://orcid.org/0000-0002-9136-9019
H J LaubachDepartment of Dermatology, Geneva University Hospitals (HUG), Geneva, Switzerland.
A M BadawiDepartment of Dermatology, Szeged University, Szeged, Hungary.ORCID https://orcid.org/0000-0002-3268-7498
A Troilius RubinDepartment of Dermatology, Skåne University Hospital, Malmö, Sweden.
M HaedersdalDepartment of Dermatology, University of Copenhagen, Bispebjerg Hospital, Copenhagen NV, Denmark.ORCID https://orcid.org/0000-0003-1250-2035
W ManuskiattiDepartment of Dermatology, Siriraj Skin Laser Center Department of Dermatology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-8393-7963
C M A M van der HorstDepartment of Plastic-, Reconstructive- and Hand Surgery, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands.
D T UbbinkDepartment of Surgery, Amsterdam University Medical Center (UMC) Location AMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9398-8879
COSCAM study group
Amsterdam University Medical Centers · NLAmsterdam Neuroscience · NLBritish Association of Dermatologists · GBCairo University · EGHospital Universitario Ramón y Cajal · ESMaastricht University Medical Centre · NLRoyal Children's Hospital · AUSiriraj Hospital · THSkåne University Hospital · SETokai University · JPUniversity Hospital of Geneva · CHUniversity of California, Irvine · USUniversity of Copenhagen · DK

Funding

UCI P30 Skin Center Systems Biology CoreP30AR075047 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANDERSEN, BOGI, GANESAN, ANAND K · 2019 to 2025
$5.1M
NIAMS NIH HHS P30 AR075047
6 · The paper itself

Abstract

backgroundDue to a large variety in treatment outcomes reported in therapeutic trials and lacking patient-relevant outcomes, it is hard to adequately compare and improve current therapies for patients with capillary malformations (CMs). The Core Outcome Set for Capillary Malformations (COSCAM) project aims to develop a core outcome set (COS) for use in future CM trials, in which we will first develop a core outcome (sub)domain set (CDS). Here, we describe the methods for the development of a CDS and present the results of the first development stage.

methodsThe COSCAM project is carried out according to the recommendations of the Cochrane Skin Core OUtcomes Set INitiative (CS-COUSIN) and the Core Outcome Measures in Effectiveness Trials (COMET) initiative. During the first stage, we identified all potentially relevant outcome subdomains based on a systematic review, two focus group sessions and input from patient representatives of Dutch patient organizations and the COSCAM-founding group. In stage two, we will present the subdomains in a three-round e-Delphi study and online consensus meeting, in which CM patients, parents/caregivers and CM experts worldwide rate the importance of the proposed subdomains, hereby finalizing the core outcome (sub)domains of the CDS.

resultsA total of 67 potential outcome subdomains were included; sixteen were previously used in the literature, 20 were proposed by Dutch patients and their parents/caregivers (n = 13) in focus group sessions and 38 were suggested by the experts of the COSCAM-founding group. Seven were excluded because of overlap.

conclusionThe final CDS may serve as a minimum standard in future CM trials, thereby facilitating adequate comparison of treatment outcomes. After this CDS development, we will select appropriate outcome measurement instruments to measure the core outcome subdomains.

Indexed as

Outcome Assessment, Health CareResearch DesignCapillariesDelphi TechniqueEndpoint DeterminationHumansSystematic Reviews as TopicTreatment OutcomeVascular Malformations

Identifiers

PMID34014582
PMCPMC8453952
OpenAlexW3162376568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.